INT49700

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1995
Last Reported 2008
Negated 3
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 1.18
Pain Relevance 3.95

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Ngf) extracellular space (Ngf) aging (Ngf)
extracellular region (Ngf) molecular_function (Ngf)
Anatomy Link Frequency
blood 2
lactotroph 2
Stem 2
mast cell 2
Ngf (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Nerve growth factor 70 100.00 Very High Very High Very High
nMDA receptor 2 99.00 Very High Very High Very High
antagonist 43 98.28 Very High Very High Very High
Thermal hyperalgesia 8 97.08 Very High Very High Very High
Glutamate 18 91.92 High High
tetrodotoxin 6 90.32 High High
bradykinin 2 88.92 High High
Action potential 4 73.92 Quite High
Peripheral sensitization 1 68.96 Quite High
Dopamine 13 62.80 Quite High
Disease Link Frequency Relevance Heat
Pressure And Volume Under Development 4 97.44 Very High Very High Very High
Hyperalgesia 8 97.08 Very High Very High Very High
Nociception 1 72.08 Quite High
Hypertension 4 70.04 Quite High
Urological Neuroanatomy 2 66.72 Quite High
INFLAMMATION 32 47.72 Quite Low
Stress 50 43.92 Quite Low
Targeted Disruption 22 5.00 Very Low Very Low Very Low
Cancer 22 5.00 Very Low Very Low Very Low
Pituitary Cancer 11 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The activity-dependent release of NGF did not depend on extracellular Ca2+, but was sensitive to the intracellular Ca2+ chelator bis-(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl)-ester, and to depletion of intracellular calcium stores.
Neg (not) Regulation (depend) of Localization (release) of NGF associated with nerve growth factor
1) Confidence 0.59 Published 1995 Journal Eur. J. Neurosci. Section Abstract Doc Link 7582095 Disease Relevance 0 Pain Relevance 0.97
In vitro, colchicine (0.4-12 microg/ml) did not significantly influence NGF (10 ng/ml)-induced histamine release from rat peritoneal cells, suggesting that a mast cell stabilizing effect of colchicine did not contribute to inhibition of NGF-induced thermal hyperalgesia.
Neg (not) Regulation (influence) of Localization (release) of NGF in mast cell associated with nerve growth factor and thermal hyperalgesia
2) Confidence 0.27 Published 1998 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 9750013 Disease Relevance 1.11 Pain Relevance 1.30
The activity-dependent release of NGF did not depend on extracellular Ca2+, but was sensitive to the intracellular Ca2+ chelator bis-(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl)-ester, and to depletion of intracellular calcium stores.
Regulation (sensitive) of Localization (release) of NGF associated with nerve growth factor
3) Confidence 0.26 Published 1995 Journal Eur. J. Neurosci. Section Abstract Doc Link 7582095 Disease Relevance 0 Pain Relevance 0.97
A possible explanation of the discrepancy in the findings is that autocrine action of endogenous NGF may be restricted to the neonatal period and that later spontaneous NGF release no longer affects lactotroph cell renewal unless NGF release is specifically activated.
Regulation (affects) of Localization (release) of NGF in lactotroph associated with nerve growth factor
4) Confidence 0.25 Published 2008 Journal Journal of Neuroendocrinology Section Body Doc Link PMC2229370 Disease Relevance 0 Pain Relevance 0.60
Moreover, the efficacy of our nerve guides can be improved by means of polymer functionalizations [43], controlled release of growth factors, such as nerve growth factor (NGF), and/or other biological cues, such as Schwann cells or Neural Stem Cells that can be introduced along the graft to promote and guide regeneration of peripheral axons in rats [23,44-47].


Regulation (controlled) of Localization (release) of NGF in Stem associated with nerve growth factor
5) Confidence 0.23 Published 2008 Journal BMC Biotechnol Section Body Doc Link PMC2358889 Disease Relevance 0 Pain Relevance 0.12
Chronic treatment with prazosin (an alpha1-adrenoreceptor antagonist, 3 mg/kg per day) failed to alter the synthesis and release of CGRP and vascular NGF content, even though it completely normalized blood pressure.
Neg (failed) Regulation (alter) of Localization (release) of NGF in blood
6) Confidence 0.23 Published 2005 Journal J. Hypertens. Section Body Doc Link 15716703 Disease Relevance 0.07 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox